全文获取类型
收费全文 | 851篇 |
免费 | 71篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 43篇 |
妇产科学 | 27篇 |
基础医学 | 114篇 |
口腔科学 | 24篇 |
临床医学 | 85篇 |
内科学 | 127篇 |
皮肤病学 | 77篇 |
神经病学 | 15篇 |
特种医学 | 94篇 |
外科学 | 58篇 |
综合类 | 65篇 |
预防医学 | 75篇 |
眼科学 | 14篇 |
药学 | 27篇 |
肿瘤学 | 75篇 |
出版年
2022年 | 7篇 |
2021年 | 7篇 |
2020年 | 10篇 |
2019年 | 12篇 |
2018年 | 11篇 |
2017年 | 11篇 |
2016年 | 15篇 |
2015年 | 22篇 |
2014年 | 15篇 |
2013年 | 19篇 |
2012年 | 25篇 |
2011年 | 36篇 |
2010年 | 34篇 |
2009年 | 27篇 |
2008年 | 37篇 |
2007年 | 36篇 |
2006年 | 32篇 |
2005年 | 42篇 |
2004年 | 23篇 |
2003年 | 20篇 |
2002年 | 37篇 |
2001年 | 21篇 |
2000年 | 27篇 |
1999年 | 32篇 |
1998年 | 34篇 |
1997年 | 28篇 |
1996年 | 22篇 |
1995年 | 20篇 |
1994年 | 16篇 |
1993年 | 16篇 |
1992年 | 20篇 |
1991年 | 10篇 |
1990年 | 11篇 |
1989年 | 27篇 |
1988年 | 18篇 |
1987年 | 25篇 |
1986年 | 15篇 |
1985年 | 12篇 |
1984年 | 9篇 |
1983年 | 11篇 |
1982年 | 10篇 |
1981年 | 11篇 |
1980年 | 12篇 |
1979年 | 4篇 |
1977年 | 3篇 |
1976年 | 5篇 |
1975年 | 8篇 |
1968年 | 2篇 |
1967年 | 2篇 |
1961年 | 2篇 |
排序方式: 共有926条查询结果,搜索用时 15 毫秒
71.
72.
73.
The incidence of thromboembolitic events in patients undergoing transfemoral angiography was examined using indium-111 labeled platelets. Twenty-seven patients received approximately 300 muCi of autologous labeled platelets at least 3 hours before angiography and were scanned with a gamma camera immediately before and after angiography. All patients were free of clinically obvious complications in the 1-2 day period after angiography. Our results showed evidence of platelet deposition at 21 sites other than the puncture site in 12 (44%) patients. Most platelet deposition (54%) occurred along the region between the puncture site and the aortic bifurcation; 24% occurred at sites not traversed by the catheter. At the puncture site itself, there was substantial platelet uptake in 44% of patients. This study indicates the need for further work in determining the most suitable catheter material and in assessing the efficacy of other measures such as anticoagulant or antiplatelet therapy. 相似文献
74.
75.
True or sham plasma exchange was done weekly for 20 weeks in patients in two of the randomization groups in a prospective, blind clinical trial of experimental treatments for multiple sclerosis. Because patients could be randomized to receive sham plasma exchange and placebo medications, it was decided when the trial was designed that the use of fistulae, arteriovenous shunts, venous cutdowns, or other aggressive forms of venous access would not be permitted for any patient. Accordingly, patients judged to have inadequate superficial antecubital veins were ineligible for the trial. To date, only 13 (4.4%) of 294 patients considered for entry into the trial have been rejected on these grounds. In only 4 of the 93 patients undergoing exchange was it necessary to discontinue plasma exchange because of inadequate venous access. In 79.3 percent of the 1207 exchanges done in these patients, there were no problems of any kind with venous access. In 5.4 percent of these 1207 exchanges, it was necessary to terminate the procedure prematurely because of difficulties with patients' veins. Thus, the great majority of patients free of serious systemic illness (other than chronic progressive multiple sclerosis) can undergo weekly plasma exchange for up to 20 weeks using superficial antecubital veins without the need to resort to more invasive methods of venous access. 相似文献
76.
Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. 总被引:4,自引:0,他引:4 下载免费PDF全文
Z Lazarova C Yee T Darling R A Briggaman K B Yancey 《The Journal of clinical investigation》1996,98(7):1509-1518
Patients with a recently identified subepithelial blistering disease have IgG anti-laminin 5 autoantibodies. To determine if such antibodies can be pathogenic in vivo, we developed and characterized rabbit anti-laminin 5 IgG, and passively transferred these antibodies to neonatal mice. Immune rabbit IgG specifically bound human and murine epidermal basement membranes, immunoblotted and immunoprecipitated all laminin 5 subunits from extracts of human and murine keratinocytes, and showed no reactivity to other keratinocyte proteins or epithelial basement membranes that do not contain laminin 5. Mice (n = 29) receiving purified anti-laminin 5 IgG developed, in a dose-related fashion, circulating anti-laminin 5 antibodies, deposits of rabbit IgG and murine C3 in epidermal basement membranes, and subepidermal blisters of skin and mucous membranes. No alterations developed in controls (n = 14) receiving identical amounts of normal rabbit IgG. Passive transfer of anti-laminin 5 (but not control) IgG to neonatal C5- (n = 3) or mast cell-deficient (n = 3) mice produced subepidermal blisters with the same clinical, histologic, and immunopathologic features as those documented in BALB/c mice. These studies establish an animal model of a human blistering disease that can be used to define disease mechanisms and treatment modalities. 相似文献
77.
In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. 总被引:5,自引:9,他引:5 下载免费PDF全文
C W Ford J C Hamel D M Wilson J K Moerman D Stapert R J Yancey Jr D K Hutchinson M R Barbachyn S J Brickner 《Antimicrobial agents and chemotherapy》1996,40(6):1508-1513
The Upjohn oxazolidinones, U-100592 and U-100766, are orally bioavailable synthetic antimicrobial agents with spectra of activity against antibiotic-susceptible and -resistant gram-positive pathogens. In several mouse models of methicillin-resistant Staphylococcus aureus infection, U-100592 and U-100766 yielded oral 50% effective doses (ED50) ranging from 1.9 to 8.0 mg/kg of body weight, which compared favorably with vancomycin subcutaneous ED50 values of 1.1 to 4.4 mg/kg. Similarly, both compounds were active versus a Staphylococcus epidermidis experimental systemic infection. U-100592 and U-100766 effectively cured an Enterococcus faecalis systemic infection, with ED50 values of 1.3 and 10.0 mg/kg, and versus a vancomycin-resistant Enterococcus faecium infection in immunocompromised mice, both drugs effected cures at 12.5 and 24.0 mg/kg. Both compounds were exceptionally active in vivo against penicillin- and cephalosporin-resistant Streptococcus pneumoniae, with ED50 values ranging from 1.2 to 11.7 mg/kg in systemic infection models. In soft tissue infection models with S. aureus and E. faecalis, both compounds exhibited acceptable curative activities in the range of 11.0 to 39.0 mg/kg. U-100766 was also very active versus the Bacteroides fragilis soft tissue infection model (ED50 = 46.3 mg/kg). In combination-therapy studies, both U-100592 and U-100766 were indifferent or additive in vivo against a monomicrobic S. aureus infection in combination with other antibiotics active against gram-positive bacteria and combined as readily as vancomycin with gentamicin in the treatment of a polymicrobic S. aureus-Escherichia coli infection. U-100592 and U-100766 are potent oxazolidinones active against antibiotic-susceptible and -resistant gram-positive pathogens in experimental systemic and soft tissue infections. 相似文献
78.
In-vitro activity of trospectomycin sulphate against Mycoplasma and Ureaplasma species isolated from humans 总被引:3,自引:0,他引:3
Trospectomycin sulphate, a novel analogue of spectinomycin, was compared to spectinomycin, tetracycline, lincosamide, macrolide, quinolone and naphthalenic ansamycin-class antibiotics for in-vitro activity against Mycoplasma pneumoniae, M. hominis and Ureaplasma urealyticum. MIC determinations were conducted by the agar dilution method using either SP-4 (Mycoplasma spp.) or A8 (U. urealyticum) agars. Trospectomycin compared favorably with tetracycline for all the strains of M. pneumoniae, M. hominis or U. urealyticum tested. Ciprofloxacin was the most active of the newer quinolones tested. Trospectomycin was as active as this quinolone antibiotic, or more active, in vitro. Other antibiotics such as the macrolides and lincosamides were highly active against one or more of the three mycoplasma groups tested but none was active against all three. The results suggest that trospectomycin may be useful in the treatment of mycoplasma-induced respiratory or genital tract infections in man. 相似文献
79.
80.
Eva Hradetzky Thomas M Sanderson Tsz M Tsang John L Sherwood Stephen M Fitzjohn Viktor Lakics Nadia Malik Stephanie Schoeffmann Michael J O'Neill Tammy MK Cheng Laura W Harris Hassan Rahmoune Paul C Guest Emanuele Sher Graham L Collingridge Elaine Holmes Mark D Tricklebank Sabine Bahn 《Neuropsychopharmacology》2012,37(2):364-377
Administration of the DNA-alkylating agent methylazoxymethanol acetate (MAM) on embryonic day 17 (E17) produces behavioral and anatomical brain abnormalities, which model some aspects of schizophrenia. This has lead to the premise that MAM rats are a neurodevelopmental model for schizophrenia. However, the underlying molecular pathways affected in this model have not been elucidated. In this study, we investigated the molecular phenotype of adult MAM rats by focusing on the frontal cortex and hippocampal areas, as these are known to be affected in schizophrenia. Proteomic and metabonomic analyses showed that the MAM treatment on E17 resulted primarily in deficits in hippocampal glutamatergic neurotransmission, as seen in some schizophrenia patients. Most importantly, these results were consistent with our finding of functional deficits in glutamatergic neurotransmission, as identified using electrophysiological recordings. Thus, this study provides the first molecular evidence, combined with functional validation, that the MAM-E17 rat model reproduces hippocampal deficits relevant to the pathology of schizophrenia. 相似文献